Peripheral Artery Disease

Adults with peripheral artery disease who participated in a high-intensity, home-based walking exercise program for 12 months experienced improvements in measures of walking impairment vs. low intensity and controls, a speaker reported.

In a pooled analysis of three single-center studies, a bioresorbable scaffold was associated with high rates of patency and low rates of adverse events at 2 years in high-risk patients with infrapopliteal artery lesions.

In a pooled analysis of two randomized controlled trials of a low-dose paclitaxel-coated balloon to treat peripheral artery disease, there was no mortality difference between the paclitaxel-coated balloon and an uncoated balloon at 4 years.

Among patients with peripheral artery disease who had an endovascular procedure, treatment with a drug-coated device was linked to lower risk for unplanned limb revascularization, according to new data from the VOYAGER PAD trial.

In patients with calcified peripheral artery lesions treated with a drug-coated balloon, those who were pretreated with intravascular lithotripsy had better procedural outcomes than those pretreated with angioplasty, a speaker said at VIVA.

In a real-world population of patients with peripheral artery disease treated with a drug-coated balloon, nearly 70% remained free from clinically driven target lesion revascularization at 5 years, according to data presented at VIVA 20.

Boston Scientific announced the FDA has approved the Ranger drug-coated balloon for the treatment peripheral artery disease in the superficial femoral artery and proximal popliteal artery.

A low-dose paclitaxel-coated balloon was safe and effective at 4 years in real-world patients with peripheral artery disease, according to the ILLUMENATE Global results presented at the virtual TCT Connect.

At 3.5 years after lower-extremity revascularization, there was no difference in mortality in the VOYAGER PAD cohort between patients with peripheral artery disease treated with paclitaxel-coated devices and those not treated with them.

September is Peripheral Artery Disease Awareness Month, designed to improve access to screening and treatments for patients with PAD.